Check4™

New CDC research shows that current rapid home tests give false results more than 50 percent of the time. Check4-COVID is intended to an over-the-counter rapid test with the accuracy of a PCR test. Reducing false negatives rapidly by this margin will be critical to slowing the spread and allowing people to return to normal.

No. Check4-COVID™ is intended to be a simple self-test, similar to a home DNA test. Check4-COVID™ allows consumers to test their saliva on a device that connects to a smartphone. Results appear on the app within minutes in the privacy of a user’s home.

Consumers buy a small, simple device and download the free smartphone app. A saliva sample is placed in the device, and the results appear within minutes on the app. It is intended that inexpensive replaceable cartridges will allow endless, affordable testing on each device.

Following FDA approval, Check4-COVID™ intends to meet the gold-standard in hospital-grade molecular COVID testing with minimal false positives. This is significantly better than current home rapid tests.

By law, all COVID test results must be reported to health authorities to help manage the pandemic. Check4-COVID™ is an electronic-based, self-test that fulfills legal reporting requirements automatically through smartphones.

Chemical-based tests often rely on visual indicators. Check4-COVID™ uses an electronic circuit, which enables a signal to be sent to smartphones. The app then reports results to health authorities, which is required by law.

The smartphone app allows multiple users on a single device. This enables family members who do not have smartphones to use the device and app belonging to someone with a smartphone.

No. A family can share the same device. The smartphone app is intended to allow multiple users so family members can share the same app and device, while interchanging different test cartridges.

By law, all test results must be reported to state and federal health authorities. All information collected by the IdentifySensors app is confidential and shared only with government agencies that require it. Some test results are de-identified, meaning that names are removed from the test results. All data is treated by the same high standards as secure hospital records. The app is securely encrypted and fully HIPAA compliant.

No. By law, all test results for contagious diseases must be reported to state, and federal health authorities. All information collected by the Check4-COVID™ app is encrypted, confidential, and follows high hospital standards for HIPAA-compliant privacy.

It is intended that the reusable reader will cost $130. Each test cartridge will cost less than $25. The accuracy of the test and the low cost are intended to promote more frequent testing.

World-renowned scientists at Purdue University, who specialize in infectious diseases, have been developing and verifying the test’s accuracy for commercialization. The test is intended to be available to consumers following FDA approval, which is anticipated this year.

New CDC research shows that more than 50 percent of current rapid test results are incorrect. Most PCR tests currently in use are expensive and take far too long for the results. These chemical-based tests often require samples to be transported to a laboratory for results.

Industry-leading scientists at Purdue University who specialize in infectious diseases have been developing and verifying the test for commercialization. The test is intended to be available to consumers following FDA approval this year.

Check4-COVID™ is intended to be sold online and through retail stores, such as pharmacies and grocery stores. High-volume commercial versions of the test are intended to be available to healthcare facilities and businesses through wholesale channels.

Yes. Check4-COVID™ is intended to be fast, inexpensive and accurate, which enables frequent self-testing at home and without wait. Individuals infected with COVID-19, who quarantine at home, can self-test as often as they like to minimize quarantine times and return to their lives as soon as possible.

Yes, IdentifySensors holds several patents on various facets of the technology. Other patents are pending.

Product development is in its final stages now. It is intended that the test will be available in 2021, following FDA approval.

Check4-COVID™ soon will be submitted for FDA approval. We cannot be sure how long that process will last, but the process typically lasts a few weeks.

The unique technology enables the test to be easily modified for other pathogens, including other coronaviruses, influenza, Zika, dengue, HIV/AIDS, hepatitis C, Lyme disease, mumps, measles, chickenpox, and methicillin-resistant staphylococcus Aureus (MRSA), as well as foodborne pathogens.

Customers and employees could be allowed into facilities more readily with more frequent testing. Offices, manufacturing facilities, and restaurants, for example, could require self-tests of their employees. Sports facilities, airlines, and concert halls, for example, could require fans to display their self-test results on their smartphones before entering.

The self-tests are intended to be fast, accurate and affordable. Frontline workers and nursing-home employees, for example, could test themselves, and their patients daily, and isolate positive cases. Slowing the spread of the virus can help hospitals manage the best use of their facilities.